ANI Pharmaceuticals price target raised to $72 from $62 at Guggenheim

Guggenheim analyst Vamil Divan raised the firm’s price target on ANI Pharmaceuticals to $72 from $62 and keeps a Buy rating on the shares after the company delivered “record” Q2 results that the firm notes were “above our recently increased expectations.” The management team was “clear” in a follow-up call “that they are continuing to include some conservative estimates in their newly updated guidance,” says the firm, which is “becoming more comfortable in assuming that the positive progress the company has demonstrated over the past few quarters will continue to benefit the company’s top and bottom line for several quarters to come.”